Abstract: Objective: To review the work‐up and inpatient management of non‐cystic fibrosis bronchiectasis exacerbations against best practice guidelines in the Kimberley, a remote region of Western Australia, with the ultimate goal of improving treatment in the region.^ Design: Retrospective cohort study and audit of remote adult bronchiectasis hospital admissions between 2011 and 2016. Setting: Remote hospital inpatients. Participants: Thirty‐two patients and 110 hospital admissions were included. Patients were ≥15 years old, had computed tomography confirmed bronchiectasis and at least one hospital admission for acute respiratory illness prior to January 2011. Main outcomes measured: The 5‐year mortality and compliance to a Lung Foundation position statement on non‐cystic fibrosis bronchiectasis which suggests investigating for an underlying cause at diagnosis and during exacerbations prolonged antibiotics (10–14 days) and prolonged hospital admissions (≥7 days) are required. Results: The overall 5‐year mortality was 21.8%, with the median age at death of 37 years (interquartile range, 27–63). The median duration of hospital admission was shorter than the recommended 3 days (interquartile range, 2–5) with 11 of 100 (11%) patients admitted for ≥7 days. The median duration of antibiotics was also shorter than the recommended 7 days (interquartile range, 4–10), with 31 of the 98 (32%) patients prescribed ≥10 days and 6 of the 98 (6%) prescribed ≥14 days of therapy. Conclusion: We found under‐treatment and under‐investigation of non‐cystic fibrosis bronchiectasis in the Kimberley region. Five‐year mortality was high, consistent with other rural Australian Indigenous cohorts.§ Following this audit, a strategy to improve awareness, as well as update and promote regional guidelines has been developed.